Congestive heart failure (CHF), often referred to simply as “heart failure,” is a chronic progressive condition that specifically refers to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Heart failure (HF) is one of the main causes of mortality and hospitalization worldwide, affecting approximately 26M people globally and 15M people in Europe. Pulmonary edema also known as lung fluid congestion is one of the main clinical conditions associated with HF, leading to hospitalization and high mortality rates. The median survival after its onset is approximately 5 years. One-year mortality is estimated at 16.5% globallyand 9.3% in Europe. Lung fluid congestion leads to a vicious cycle of repeated hospitalizations of HF patients, with 24% of patients readmitted to hospital within 30 days and 50% of patients readmitted within 6 months. The key challenge is to enable early detection and timely treatment of symptoms, before the patient undergoes respiratory distress leading to hospitalization. ReDS™ is a groundbreaking non-invasive home monitoring system for accurate, actionable and absolute measurement of lung fluid content. The monitoring procedure takes only 90 seconds and the results are shared automatically with the healthcare professionals through cloud based deterioration prediction platform. ReDS™ uses unique radar technology, and is the first solution that enables accurate measurement, remote monitoring and management of fluid congestion in HF patients. Crucially, ReDS™ provides early, pre-symptomatic detection of lung fluid accumulation allowing preventative measures to be taken. The overall objective is to commercialize ReDS in the European market and beyond for patient home monitoring, substantially reducing readmissions to hospital for HF patients.
